Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MedRing intravaginal oxybutynin versus oral oxybutynin crossover study
NL-OMON53442Active, not recruiting
- Sponsor
- LiGalli
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of oxybutynin in overactive bladder (OAB) (3 arms), sponsored by LiGalli. Primary endpoints: Adaptive tracking average performance, Saccadic reaction time and 19 more. Started Sep 2022; status: active, not recruiting.
02
Drugs
oxybutynin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NL-OMON53442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53442.